Glenmede Trust’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Glenmede Trust’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,502	Closed	-$591K	–	1386
2023 Q2	$591K	Hold	6,502	–	–	﹤0.01%	790
2023 Q1	$591K	Buy	+6,502	New	+$382K	﹤0.01%	793
2020 Q4	–	Sell	-400	Closed	-$38K	–	2397
2020 Q3	$38K	Sell	400 -662	-62%	-$82.7K	﹤0.01%	1411
2020 Q2	$165K	Sell	1,062 -673	-39%	-$102K	﹤0.01%	1055
2020 Q1	$354K	Hold	1,735	–	–	﹤0.01%	1003
2019 Q4	$354K	Buy	1,735 +1,266	+270%	+$231K	﹤0.01%	1003
2019 Q3	$37	Buy	469 +9	+2%	+$764	﹤0.01%	1801
2019 Q2	$43	Hold	460	–	–	﹤0.01%	1756
2019 Q1	$39	Buy	+460	New	+$38.2K	﹤0.01%	1800

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust's RETA Position: Q3 2023 in Review

Glenmede Trust sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 6,502 shares — an estimated $591K sold.

Glenmede Trust first reported a position in RETA in Q1 2019 and held it in 9 quarters. The position peaked at $591K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Glenmede Trust reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Glenmede Trust sold 6,502 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $591K.
Glenmede Trust first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 9 quarters.
Glenmede Trust's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $591K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Glenmede Trust's 13F filing for Q3 2023, filed 14 Nov 2023.